Provided by Tiger Fintech (Singapore) Pte. Ltd.

OncoCyte Corporation

2.77
-0.0400-1.42%
Post-market: 2.770.00000.00%16:05 EDT
Volume:49.58K
Turnover:133.38K
Market Cap:79.22M
PE:-0.59
High:2.82
Open:2.82
Low:2.57
Close:2.81
Loading ...

Company Profile

Company Name:
OncoCyte Corporation
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
48
Office Location:
15 Cushing,Irvine,California,United States
Zip Code:
92618
Fax:
- -
Introduction:
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Directors

Name
Position
Andrew Arno
Chairman of the Board
Joshua Riggs
President and Chief Executive Officer and Director
Louis E. Silverman
Lead Independent Director
Alfred D. Kingsley
Director
Andrew J. Last
Director
Jennifer Levin Carter
Director
John Peter Gutfreund
Director

Shareholders

Name
Position
Joshua Riggs
President and Chief Executive Officer and Director
Anish John
Chief Financial Officer
James Liu
Controller and Principal Accounting Officer